Payment overview · 2025
General Payments
$15.99
1 reported records · 1 companies
Healthcare provider profile · identity verified
Douglas J Bower, MD
Allopathic & Osteopathic Physicians|Internal Medicine · CARLISLE, PA · NPI 1376539858
Verified facts
What the public records show
CMS Open Payments records show Douglas J Bower, MD received $15.99 in general payments during 2025 across 1 reported records.
AstraZeneca Pharmaceuticals LP accounted for 100.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 1 associated product.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Farxiga by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $15.99 | 100.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Education | $15.99 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $15.99 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 855 | 239 |
| Amlodipine Besylate | Amlodipine Besylate | 555 | 147 |
| Losartan Potassium | Losartan Potassium | 410 | 104 |
| Levothyroxine Sodium | Levothyroxine Sodium | 383 | 96 |
| Omeprazole | Omeprazole | 340 | 96 |
| Lisinopril | Lisinopril | 309 | 86 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 306 | 77 |
| Metoprolol Succinate | Metoprolol Succinate | 287 | 74 |
| Simvastatin | Simvastatin | 281 | 72 |
| Tamsulosin Hcl | Tamsulosin Hcl | 211 | 58 |
| Gabapentin | Gabapentin | 210 | 57 |
| Furosemide | Furosemide | 202 | 47 |
| Potassium Chloride | Potassium Chloride | 202 | 47 |
| Pantoprazole Sodium | Pantoprazole Sodium | 201 | 53 |
| Hydrochlorothiazide | Hydrochlorothiazide | 199 | 55 |
| Escitalopram Oxalate | Escitalopram Oxalate | 192 | 41 |
| Sertraline Hcl | Sertraline Hcl | 173 | 41 |
| Pravastatin Sodium | Pravastatin Sodium | 155 | 37 |
| Metformin Hcl Er | Metformin Hcl | 150 | 45 |
| Eliquis | Apixaban | 145 | 34 |
| Trazodone Hcl | Trazodone Hcl | 128 | 31 |
| Clopidogrel | Clopidogrel Bisulfate | 127 | 40 |
| Atenolol | Atenolol | 125 | 32 |
| Montelukast Sodium | Montelukast Sodium | 122 | 31 |
| Ezetimibe | Ezetimibe | 116 | 33 |
| Metformin Hcl | Metformin Hcl | 116 | 32 |
| Allopurinol | Allopurinol | 114 | 31 |
| Glipizide Er | Glipizide | 110 | 25 |
| Prednisone | Prednisone | 107 | 78 |
| Duloxetine Hcl | Duloxetine Hcl | 105 | 29 |
| Famotidine | Famotidine | 105 | 34 |
| Lorazepam | Lorazepam | 101 | 34 |
| Pioglitazone Hcl | Pioglitazone Hcl | 100 | 30 |
| Metoprolol Tartrate | Metoprolol Tartrate | 94 | 26 |
| Synthroid | Levothyroxine Sodium | 94 | 21 |
| Fluticasone Propionate | Fluticasone Propionate | 89 | 38 |
| Tramadol Hcl | Tramadol Hcl | 84 | 30 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 74 | 14 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 73 | 39 |
| Citalopram Hbr | Citalopram Hydrobromide | 73 | 17 |
| Ozempic | Semaglutide | 73 | 13 |
| Glimepiride | Glimepiride | 71 | 20 |
| Topiramate | Topiramate | 71 | 21 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 69 | 30 |
| Buspirone Hcl | Buspirone Hcl | 68 | 16 |
| Irbesartan | Irbesartan | 68 | 16 |
| Fluoxetine Hcl | Fluoxetine Hcl | 62 | 17 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 59 | 16 |
| Januvia | Sitagliptin Phosphate | 57 | 11 |
| Ropinirole Hcl | Ropinirole Hcl | 57 | suppressed |
| Fenofibrate | Fenofibrate | 54 | 12 |
| Mirtazapine | Mirtazapine | 54 | 20 |
| Zolpidem Tartrate | Zolpidem Tartrate | 51 | 14 |
| Bupropion Xl | Bupropion Hcl | 50 | 17 |
| Clonazepam | Clonazepam | 50 | suppressed |
| Carvedilol | Carvedilol | 49 | 14 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 49 | 12 |
| Ibandronate Sodium | Ibandronate Sodium | 48 | suppressed |
| Jardiance | Empagliflozin | 48 | 15 |
| Xarelto | Rivaroxaban | 48 | 12 |
| Memantine Hcl | Memantine Hcl | 47 | suppressed |
| Alprazolam | Alprazolam | 44 | 12 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 44 | 11 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 43 | 11 |
| Celecoxib | Celecoxib | 42 | 14 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 42 | 13 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 42 | 13 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 42 | 15 |
| Paroxetine Hcl | Paroxetine Hcl | 42 | suppressed |
| Spironolactone | Spironolactone | 42 | 12 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 41 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 40 | 36 |
| Amitriptyline Hcl | Amitriptyline Hcl | 38 | 12 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 36 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 36 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 35 | suppressed |
| Colchicine | Colchicine | 33 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 32 | suppressed |
| Finasteride | Finasteride | 31 | suppressed |
| Klor-Con M20 | Potassium Chloride | 31 | 12 |
| Tizanidine Hcl | Tizanidine Hcl | 28 | suppressed |
| Trulicity | Dulaglutide | 28 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 27 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 27 | suppressed |
| Diazepam | Diazepam | 27 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 27 | suppressed |
| Mounjaro | Tirzepatide | 27 | suppressed |
| Meloxicam | Meloxicam | 26 | 11 |
| Nitroglycerin | Nitroglycerin | 25 | 22 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 25 | suppressed |
| Valsartan | Valsartan | 24 | suppressed |
| Glipizide | Glipizide | 23 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 23 | suppressed |
| Digoxin | Digoxin | 22 | suppressed |
| Cephalexin | Cephalexin | 21 | 19 |
| Hydralazine Hcl | Hydralazine Hcl | 21 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 21 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 21 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 21 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 20 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 20 | 11 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 20 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 20 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 19 | suppressed |
| Levetiracetam | Levetiracetam | 19 | suppressed |
| Pregabalin | Pregabalin | 19 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 19 | suppressed |
| Telmisartan | Telmisartan | 19 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 18 | suppressed |
| Sucralfate | Sucralfate | 18 | suppressed |
| Candesartan-Hydrochlorothiazid | Candesartan/Hydrochlorothiazid | 17 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 17 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 17 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 16 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 16 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 16 | suppressed |
| Verapamil Sr | Verapamil Hcl | 16 | suppressed |
| Amoxicillin | Amoxicillin | 15 | suppressed |
| Baclofen | Baclofen | 15 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 15 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 15 | 14 |
| Sumatriptan Succinate | Sumatriptan Succinate | 15 | suppressed |
| Torsemide | Torsemide | 15 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 14 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 14 | suppressed |
| Lovastatin | Lovastatin | 14 | suppressed |
| Myrbetriq | Mirabegron | 14 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 14 | 13 |
| Warfarin Sodium | Warfarin Sodium | 14 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Cevimeline Hcl | Cevimeline Hcl | 13 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 13 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 13 | suppressed |
| Oxycontin | Oxycodone Hcl | 13 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 13 | 13 |
| Repaglinide | Repaglinide | 13 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 13 | suppressed |
| Tiadylt Er | Diltiazem Hcl | 13 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 13 | suppressed |
| Bumetanide | Bumetanide | 12 | suppressed |
| Fluocinolone Acetonide Oil | Fluocinolone Acetonide Oil | 12 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 12 | suppressed |
| Novolog Flexpen | Insulin Aspart | 12 | suppressed |
| Pradaxa | Dabigatran Etexilate Mesylate | 12 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 12 | suppressed |
| Entresto | Sacubitril/Valsartan | 11 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 11 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 11 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 11 | suppressed |
| Indomethacin | Indomethacin | 11 | suppressed |
| Lamotrigine | Lamotrigine | 11 | suppressed |
| Temazepam | Temazepam | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $15.99 · 1 records | AstraZeneca Pharmaceuticals LP | BREZTRI | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error